Long-Term Nitrate Use in Acute Myocardial Infarction (The Heart Institute of Japan, Department of Cardiology Nitrate Evaluation Program)

Takao, Yoshinori; Hagiwara, Nobuhisa; Kasanuki, Hiroshi; Koyanagi, Ryo

doi:10.1007/s10557-008-6089-8

Cited by 10 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the author acknowledged the limitation of the study, as the difference may be attributed to, among other uncontrolled factors, an increased frequency of nitrate use in patients with more severe conditions. 79 Information on the consequence of nitroglycerin tolerance will be valuable for a better clinical use of nitroglycerin and other nitrates in the treatment of patients with angina-related cardiovascular diseases.…”

Section: Angina Nitroglycerin Bioactivation Tolerance and Aldh2mentioning

confidence: 99%

Mitochondrial aldehyde dehydrogenase and cardiac diseases

Chen

Sun

Mochly‐Rosen

2010

Cardiovascular Research

184

166

View full text Add to dashboard Cite

Numerous conditions promote oxidative stress, leading to the build-up of reactive aldehydes that cause cell damage and contribute to cardiac diseases. Aldehyde dehydrogenases (ALDHs) are important enzymes that eliminate toxic aldehydes by catalysing their oxidation to non-reactive acids. The review will discuss evidence indicating a role for a specific ALDH enzyme, the mitochondrial ALDH2, in combating oxidative stress by reducing the cellular ‘aldehydic load’. Epidemiological studies in humans carrying an inactive ALDH2, genetic models in mice with altered ALDH2 levels, and small molecule activators of ALDH2 all highlight the role of ALDH2 in cardioprotection and suggest a promising new direction in cardiovascular research and the development of new treatments for cardiovascular diseases.

show abstract

Section: Angina Nitroglycerin Bioactivation Tolerance and Aldh2mentioning

confidence: 99%

Mitochondrial aldehyde dehydrogenase and cardiac diseases

Chen

Sun

Mochly‐Rosen

2010

Cardiovascular Research

184

166

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of the use of nitroglycerin and nitroprusside (NO donors) in acute myocardial infarct suggested that nitrates reduced mortality be around a third (Yusuf et al, 1988). Conversely, more recent studies failed to identify any benefits or improved clinical outcome associated with long-term nitrite usage (Group, 1994; Yamauchi et al, 2008), whilst another study suggested that nitrate therapy subsequent to acute coronary events increased mortality (Nakamura et al, 1999). However, while the effect on mortality have varied significantly, NO targeted therapeutics appear to be cardioprotective.…”

Section: Nitric Oxide and Caveolin-1 Therapeuticsmentioning

confidence: 99%

Caveolin as a potential drug target for cardiovascular protection

Sellers¹,

Trane²,

Bernatchez³

2012

Front. Physio.

View full text Add to dashboard Cite

Caveolae and caveolin are key players in a number of disease processes. Current research indicates that caveolins play a significant role in cardiovascular disease and dysfunction. The far-reaching roles of caveolins in disease and dysfunction make them particularly notable therapeutic targets. In particular, caveolin-1 (Cav-1) and caveolin-3 (Cav-3) have been identified as potential regulators of vascular dysfunction and heart disease and might even confer cardiac protection in certain settings. Such a central role in vascular health therefore makes manipulation of Cav-1/3 function or expression levels clear therapeutic targets in a variety of cardiovascular related disease states. Here, we highlight the role of Cav-1 and Cav-3 in cardiovascular health and explore the potential of Cav-1 and Cav-3 derived experimental therapeutics.

show abstract

“…In this issue of the journal, Yamauchi et al [1] provide further insights into the above observational studies and highlight the importance of patient selection bias. In their study, they initially assessed over 3,000 consecutive Fig.…”

Section: What Is the Clinical Evidence?mentioning

confidence: 99%